Free Trial

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

→ What President Biden's new law means for investors (From Stansberry Research) (Ad)
Free VRTX Stock Alerts
$440.61
-5.26 (-1.18%)
(As of 12:15 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 25 Analyst Ratings

Consensus Price Target

$432.18
-1.91% Downside
High Forecast$540.00
Average Forecast$432.18
Low Forecast$325.00
TypeCurrent Forecast
5/22/23 to 5/21/24		1 Month Ago
4/22/23 to 4/21/24		3 Months Ago
2/21/23 to 2/21/24		1 Year Ago
5/22/22 to 5/22/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
Hold
7 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
5 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$432.18$429.45$417.27$352.59
Forecasted Upside-1.91% Downside7.51% Upside4.91% Upside12.94% Upside
Get Vertex Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter.

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Vertex Pharmaceuticals Stock vs. The Competition

TypeVertex PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.48
2.69
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside-1.87% Downside693.50% Upside8.28% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Forecasts and Stock Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/7/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetSector Perform ➝ Sector Perform$417.00 ➝ $424.00+4.22%
5/7/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$450.00 ➝ $456.00+13.29%
5/7/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingHold
5/7/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$462.00+14.78%
4/18/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$445.00 ➝ $450.00+14.47%
4/17/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$498.00 ➝ $466.00+18.54%
4/15/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$500.00+26.09%
4/12/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingSell ➝ Sell$371.00-6.80%
4/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeIn-Line ➝ Outperform$438.00+10.17%
2/20/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$440.00+5.51%
2/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$515.00+23.24%
2/6/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$500.00 ➝ $540.00+29.71%
2/6/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$446.00 ➝ $472.00+12.48%
2/6/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform
2/2/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
2/1/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$390.00 ➝ $438.00+1.01%
1/31/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$456.00 ➝ $508.00+17.88%
1/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeNeutral ➝ Underperform$325.00-25.27%
1/31/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
11/22/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingHold ➝ Hold$373.00+5.81%
11/8/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$359.00 ➝ $364.00-3.44%
11/7/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$389.00 ➝ $415.00+8.17%
7/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$350.00 ➝ $400.00+10.55%
6/26/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingReiterates
5/25/2023Westpark Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold
3/29/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$340.00 ➝ $350.00+11.73%
2/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$374.00 ➝ $365.00+18.30%
2/8/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$374.00 ➝ $365.00+18.30%
12/19/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$340.00+11.55%
10/28/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$315.00 ➝ $330.00+10.34%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:41 PM ET.

VRTX Frequently Asked Questions

What is Vertex Pharmaceuticals's stock forecast and purchase recommendation?

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $432.18, with a high forecast of $540.00 and a low forecast of $325.00. The consensus rating for Vertex Pharmaceuticals stock is Hold based on the current 3 sell ratings, 7 hold ratings and 15 buy ratings for VRTX. Learn more on VRTX's analyst rating history.

Do Wall Street analysts like Vertex Pharmaceuticals more than its competitors?

Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating for Vertex Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VRTX compares to other companies.

Is Vertex Pharmaceuticals being upgraded by Wall Street analysts?

Over the previous 90 days, Vertex Pharmaceuticals's stock had 1 upgrade by analysts.

Does Vertex Pharmaceuticals's stock price have much upside?

According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 7.86% based on their 12-month stock forecasts.

What analysts cover Vertex Pharmaceuticals?

Vertex Pharmaceuticals has been rated by research analysts at Canaccord Genuity Group, Evercore ISI, Guggenheim, HC Wainwright, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, and UBS Group in the past 90 days.


Stock Forecasts and Research Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:VRTX) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners
4 Cryptos BETTER than Bitcoin
True Market Insiders
[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
Next President (Not Trump. Not Biden.)
The Freeport Society
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Warren Buffett's "mystery stock"
Stansberry Research
This Could be Your “Big Money” AI Moment
InvestorPlace
Elon to Transform U.S. Economy?
Porter & Company